
    
      The study consists of two groups of children to be recruited in different centers in India.
      One group will receive the HRV vaccine and one group will receive the placebo. The vaccine or
      placebo will be administered starting at 8-12 weeks of age, according to a two dose schedule
      (0, 1 months schedule). The study will consist of three visits. A 8-day (Day 0 - 7) follow-up
      period will be observed for general symptoms solicited in the study. A 31-day (Day 0 - 30)
      follow-up will be observed for other unsolicited symptoms. Serious adverse events (SAEs) will
      be followed-up throughout the study. A stool sample will be collected from the child at any
      point during the study if he/ she develops any GE.
    
  